You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Long-Term Effect of Ocrelizumab on Brain Volume and Lesion Activity Outcomes in Patients with Relapsing Multiple Sclerosis: Analysis of 10-Year Data from the OPERA Trials
This study reported rates of brain atrophy and presence of acute/chronic lesion activity over 10 years in people with RMS enrolled in the OPERA I/II trials and assessed the effect of early vs delayed initation of ocrelizumab.
Request medical material
Would you like to receive this poster via email to view later?